Prana shares up premarket on clinical trial update

Shares of Prana Biotechnology (NASDAQ:PRAN) are up 13% premarket on robust volume in response to the company's disclosure of results from a Phase 2 clinical trial of PBT2 as a treatment for patients with Alzheimer's disease.

In a sub-analysis of results originally disclosed on March 31, 2014 Professor Colin Masters found that the subgroup of PBT2-treated patients with a baseline SUVR above the Phase 2 trial mean of 2.5 showed a significant decrease in amyloid burden compared to placebo and compared to the test group with an SUVR value below 2.5. His findings will impact the design of future clinical trials to assess the safety and efficacy of PBT2 in this subgroup of AD sufferers.

From other sites
Comments (2)
  • funfundvierzig
    , contributor
    Comments (4897) | Send Message
    Alas, confirmation of the promising potential of this compound developed so assiduously by Prana's intensely-focussed people over so many years!


    And hope for the millions of families contending with this otherwise hopeless terminal disease.


    17 Jul 2014, 09:47 AM Reply Like
  • danloh
    , contributor
    Comment (1) | Send Message
    Does Prana have the financial strength to continue development of this and other potential candidates fully?
    21 Jul 2014, 06:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs